+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Screening and identification of serum proteomic biomarkers for gastric adenocarcinoma

Screening and identification of serum proteomic biomarkers for gastric adenocarcinoma

Experimental and Therapeutic Medicine 3(6): 1005-1009

The aim of the present study was to screen for possible serum biomarkers for gastric adenocarcinoma. Surface-enhanced laser desorption ionization time of flight mass spectrometry (SELDI-TOF-MS) was used to screen serum samples from 109 cases of gastric adenocarcinoma and 106 control subjects (60 healthy subjects, 30 patients with chronic superficial gastritis and 16 cases of chronic atrophic gastritis). The differentially expressed protein peaks were selected and isolated using high performance liquid chromatography (HPLC) and processed with enzyme prior to liquid chromatography-mass spectrometry tandem mass spectrometry (LC-MS/MS) analysis and data mining with software XCalibur program components BioWorks 3.2. Among the gastric cancer cases, three differentially expressed protein peaks were selected as potential serum biomarkers: the m/z peaks at 5,906.5 showed increased expression (8.53±4.33 in the cancer group, and 0.88±0.31 in the control group); the m/z peaks at 6,635.7 and 8,716.3 showed decreased expression (6.54±2.44 and 0.93±0.29, respectively, in the cancer group and 17.56±4.43 and 2.16±0.98, respectively, in the control group) (P<0.01). The m/z peaks at 5,906.5, 6,635.7 and 8,716.3, were identified as fibrinogen α-chain, apolipo-protein A-II and apolipoprotein C-I. The combined use of the three biomarkers distinguished the cancer group patients from the control group samples at a sensitivity of 93.85% (61/65) and a specificity of 94.34% (50/53). In conclusion, fibrinogen α-chain, apolipoprotein A-II and apolipoprotein C-I were identified as potential markers for gastric cancer and appear to have diagnostic value for clinical applications.

(PDF emailed within 0-6 h: $19.90)

Accession: 055670219

Download citation: RISBibTeXText

PMID: 22970007

DOI: 10.3892/etm.2012.515

Related references

Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Science 100(12): 2292-2301, 2010

Proteomic identification of serum biomarkers for gastric cancer using multi-dimensional liquid chromatography and 2D differential gel electrophoresis. Clinica Chimica Acta; International Journal of Clinical Chemistry 413(13-14): 1098-1106, 2012

Screening and identification of potential biomarkers and establishment of the diagnostic serum proteomic model for the Traditional Chinese Medicine Syndromes of tuberculosis. Journal of Ethnopharmacology 155(2): 1322-1331, 2015

Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma. Proteomics 14(7-8): 945-955, 2014

Early Identification of Bronchopulmonary Dysplasia Using Novel Biomarkers by Proteomic Screening. American Journal of Respiratory and Critical Care Medicine 197(8): 1076-1080, 2017

Serum proteomic approach for the identification of serum biomarkers contributed by oral squamous cell carcinoma and host tissue microenvironment. Journal of Proteome Research 8(5): 2173-2185, 2009

Proteomic Screening for Serum Biomarkers for Cervical Cancer and Their Clinical Significance. Medical Science Monitor 25: 288-297, 2019

Proteomic screening using SELDI-TOF to detect biomarkers for endometrial cancer in serum. Proceedings of the American Association for Cancer Research Annual Meeting 44: 93-94, July, 2003

Proteomic serum biomarkers and their potential application in cancer screening programs. International Journal of Molecular Sciences 11(11): 4175-4193, 2010

Are serum protein biomarkers derived from proteomic analysis useful in screening for trisomy 21 at 11-13 weeks?. Fetal Diagnosis and Therapy 30(1): 53-59, 2011

Validation of serum biomarkers derived from proteomic analysis for the early screening of preeclampsia. Disease Markers 2015(): 121848-121848, 2015

Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics 5(17): 4625-4636, 2005

Identification of serum biomarkers for colon cancer by proteomic analysis. British Journal of Cancer 94(12): 1898-1905, 2006

Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis. Cancer 112(3): 544-551, 2007

Proteomic analysis of serum, plasma, and lymph for the identification of biomarkers. Proteomics. Clinical Applications 1(8): 747-757, 2007